Transfection of PC3 cells by the association of DreamFect transfection reagent and magnetic nanoparticles

70% of transfection efficiency was obtained by transfecting PC3 cells with GFP plasmid using DreamFect associated to CombiMag transfection reagents.

This patent demonstrates the high efficiency of Magnetofection (CombiMag) to enhance transfection efficiency by DreamFect in PC3 cells.

Patent reference: US 2013/0274199 A1 - October 2013

Partial Fragment of REIC/Dkk-3 Gene and Cancer Therapeutic Agent Comprising the Same

Kumon, Hiromi, Huh, Nam-ho, Sakaguchi, Masakiyo, Nasu, Yasutomo, Abarzua Cabezas

abstract
This invention provides an inducer of apoptosis in cancer cells comprising a fragment of the REIC/Dkk-3 gene and a cancer therapeutic agent comprising the same. This invention also provides a polynucleotide fragment encoding the REIC/Dkk-3 protein (a) or (b), which encodes a polypeptide having apoptosis activity: (a) a polynucleotide encoding a polypeptide comprising an amino acid sequence of amino acid 1 to any of amino acids 39 to 78 of the amino acid sequence of the REIC/Dkk-3 protein as shown in SEQ ID NO: 2; or (b) a polynucleotide encoding a polypeptide comprising an amino acid sequence derived from the amino acid sequence of amino acid 1 to any of amino acids 39 to 78 of the amino acid sequence of the REIC/Dkk-3 protein as shown in SEQ ID NO: 2 by substitution, deletion, or addition of 1 or several amino acids and having apoptosis activity.

This is an association of DreamFect and CombiMag reagents. DreamFect™ formulation is a lipofection reagent achieving high transfection efficiency and high transgene expression level. CombiMag is a Magnetofection™ reagent: versatile and improving transfection efficiency without toxicity. This association combines both of the advantages of lipofection and magnetofection transfection technique to transfect all kind of cells with the best efficiency!